| Drug Name | ( Saxenda® (liraglutide |
|---|---|
| Drug Class |
Anti-diabetic
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
patient guide
|
| Specialty (Theraputic area) |
Endocrine
|
| Risk |
Cancers and tumours (neoplasms) including breast cancer, pancreatic cancer and medullary thyroid Risk of thyroid C-cell tumors and acute pancreatitis |
| patient guide |
|
| Dear Healthcare provider letter DHPC |
|